Impact of statins therapy on morphological changes in lipid-rich plaques stratified by 10-Year framingham risk score: A serial optical coherence tomography study
Metrics: PDF 872 views | HTML 1485 views | ?
Yinchun Zhu1,*, Lin Lin1,*, Chao Wang1,*, Haibo Jia1, Sining Hu1, Lulu Li1, Xiling Zhang1, Gonghui Zheng1, Yan Wang1, Rong Sun1, Abigail Afolabi1, Irina Mustafina1, Jingbo Hou1, Shaosong Zhang2, Bo Yu1
1Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China
2Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
*These authors have contributed equally to this work
Bo Yu, email: firstname.lastname@example.org
Haibo Jia, email: email@example.com
Keywords: statins therapy, morphological changes, lipid-rich plaques, framingham risk score, optical coherence tomography
Received: August 24, 2016 Accepted: January 16, 2017 Published: March 14, 2017
The aim of the study was to investigate the impact of statins therapy on morphological changes of lipid-rich plaques by OCT (optical coherence tomography) in patients with known CHD (coronary heart disease), stratified by FRS. Ninety-seven lipid-rich plaques from sixty-nine patients who received statins therapy and underwent serial OCT images (baseline, 6-month and 12-month) were divided into 2 groups according to the FRS (framingham risk score): low risk group A (FRS<10%, N=35, n=45), moderate to high risk group B (FRS≥10%, N=34, n=52). Fibrous cap thickness (FCT) was measured at its thinnest part 3 times. Baseline characteristics were not different between the 2 groups. FCT sustained increased from baseline to 6-month and 12-month follow up in both group A (59.8±20.4μm, 118.3±62.5μm, and 158.8±83.4μm respectively, P<0.001) and group B (62.2±16.8μm, 125.1±78.7μm, 163.8±75.5μm respectively, P<0.001). Lipid index was significantly decreased in both group A (1862.1±1164.5, 1530.3±1108.7, 1322.9±1080.4, P<0.001) and group B (1646.6±958.5, 1535.1±1049.1, 1258.6±1045, P=0.016). The incidence of TCFA was decreased statistically in both group A (P <0.001) and group B (P <0.001). The patients with known CHD can equivalently benefit from statins therapy by stabilizing the lipid-rich plaques. Patients with moderate to high FRS might benefit more within the first year from event time.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.